EcoDrugPlus

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSORLG00000010042
Gene Symbol: AGTR1
1 Cross references
198 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSORLG00000008388
Gene Symbol: AGTR2
4 Cross references
185 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSORLG00000002666
Gene Symbol: APLNR2
4 Cross references
171 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSORLG00000010331
Gene Symbol: ALOX12
4 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase A

Ensembl ID : ENSORLG00000007461
Gene Symbol: ALOX5A
4 Cross references
225 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSORLG00000027016
Gene Symbol: ALOX5AP
4 Cross references
200 Possible Orthologues:

Arg8-Vasotocin Receptor-Like

Ensembl ID : ENSORLG00000017245
Gene Symbol: V1AR1
3 Cross references
195 Possible Orthologues:

Arginine Vasopressin Receptor 1aa

Ensembl ID : ENSORLG00000002126
Gene Symbol: AVPR1AA
3 Cross references
170 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSORLG00000007088
Gene Symbol: AVPR2
3 Cross references
178 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSORLG00000016671
Gene Symbol: AVPR2
4 Cross references
148 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSORLG00000005631
Gene Symbol: AURKA
4 Cross references
232 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSORLG00000000578
Gene Symbol: AURKB
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).